SAN DIEGO—(BUSINESS WIRE)—Aug. 9, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system disorders,today announced the pricing of an underwritten public offering of6,060,606 shares of its common stock, offered at a price to the publicof $33.00 per share. The gross proceeds from this offering to ACADIA areexpected to be approximately $200.0 million, before deductingunderwriting discounts and commissions and other estimated offeringexpenses payable by ACADIA. ACADIA has granted the underwriters a 30-dayoption to purchase up to an aggregate of 909,090 additional shares ofcommon stock. The offering is expected to close on August 15, 2016,subject to customary closing conditions.
J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA Merrill Lynchare acting as the joint book-running managers for the offering. Cowenand Company, LLC, Piper Jaffray & Co. and Needham & Company, LLC areacting as co-managers for the offering.
The shares of common stock described above are being offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective on March 3, 2014. A preliminary prospectus supplement relatedto the offering was filed with the SEC and is available on the SEC’swebsite located at http://www.sec.gov.Copies of the final prospectus supplement and the accompanyingprospectus related to this offering, when available, may be obtainedfrom J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)803-9204, or by email to: prospectus-eq_fi@jpmchase.com,or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 WestStreet, New York, NY 10282, or by telephone at (866) 471-2526, or byemail to: prospectus-ny@ny.email.gs.com,or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rdfloor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or byemail to: dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature, including statements related to the expected proceeds and timingof the offering of common stock by ACADIA, are forward-lookingstatements. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingmarket risks and uncertainties and the satisfaction of customary closingconditions for an offering of securities. For a discussion of these andother factors, please refer to ACADIA’s annual report on Form 10-K forthe year ended December 31, 2015 as well as ACADIA’s subsequent filingswith the Securities and Exchange Commission. You are cautioned not toplace undue reliance on these forward-looking statements, which speakonly as of the date hereof. This caution is made under the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, SeniorDirector, Investor Relations
(858) 558-2871